Healthcare professionals who manage patients with hemophilia can enhance their knowledge of gene therapy for hemophilia.
coreHEM has produced the first set of guidelines recommending a specific, minimum set of outcomes to include in hemophilia gene therapy clinical trials.
In recognition of National Nurses Week, Mary Lesh, RN, MS, CPNP speaks of the care HTC nurses provide to people with bleeding disorders.
The workshop aims to solicit hemophilia community-wide input into a coordinated national blueprint for future research on factor VIII immunogenicity and factor VIII inhibitor prevention and eradication.
OIC study suggests that enhanced education on intravenous self-infusion of factor therapy can significantly reduce prosthetic joint infections for hemophilia patients.
Swedish and U.S. researchers sought to uncover potential correlations between VWD prophylaxis and hospitalizations.
There is no time like spring with its milder temperatures to get re-energized and become more committed to your health through exercise and nutrition.
Shire recently announced that the FDA has approved VONVENDI® for perioperative management of bleeding in adults with VWD.
Emicizumab-kxwh (HEMLIBRA, Genentech) was approved for use by the US Food and Drug Administration on November 16, 2017 for individuals with hemophilia A and inhibitors.
NHF's MASAC has issued the latest revision to their most comprehensive treatment document.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car